AI Takeaway
Regeneron delivered modest FY2025 revenue growth of 1.0% to $14.3B, but operating income fell 10.3% as R&D spending surged 14.0% to $5.85B, while strong operating cash flow of $4.98B and robust capital returns underscored the company's financial resilience.
Revenue
$14.34B
++0.99% YoY
EPS (Basic)
$43.07
++5.31% YoY
Operating Income
$3.58B
-10.34% YoY
Filed · Analysis updated · Source: SEC EDGAR 10-K filing
Total revenue grew 1.0% year-over-year to $14.34B in FY2025 (vs. $14.20B in FY2024), reflecting steady but slowing top-line momentum as the company continues to invest heavily in its pipeline rather than relying solely on existing product sales.
Source: Source: 10-K Income Statement
R&D expenses jumped 14.0% to $5.85B in FY2025 from $5.13B in FY2024, reflecting Regeneron's aggressive pipeline expansion. This drove operating income down 10.3% to $3.58B and compressed operating margin by approximately 315 basis points to 24.9%.
Source: Source: 10-K Income Statement
Selling, General & Administrative expenses declined 8.6% to $2.70B from $2.95B in FY2024, demonstrating improved cost discipline in commercial operations that partially cushioned the impact of higher R&D investment on overall profitability.
Source: Source: 10-K Income Statement
2 more insights available
Upgrade to unlockRegeneron's R&D spending reached $5.85B in FY2025, representing approximately 40.8% of total revenue — an unusually high ratio that reflects heavy pipeline investment. If key pipeline candidates fail in late-stage trials, the company faces significant sunk costs with limited near-term revenue offset, potentially impairing future earnings growth.
Source: Source: 10-K Income Statement
Unlock 4 more detailed risk analysis
Upgrade to unlockReported EPS of $11.44 versus the $10.83 analyst consensus — a +5.7% beat for FY2025.
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $14.34B | $14.2B | +0.99% |
Operating Income | $3.58B | $3.99B | -10.34% |
Net Income | $4.5B | $4.41B | +2.09% |
EPS (Basic) | $43.07 | $40.90 | +5.31% |
EPS (Diluted) | $41.48 | $38.34 | +8.19% |
R&D Expense | $5.85B | $5.13B | +13.99% |
SG&A Expense | $2.7B | $2.95B | -8.61% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $40.56B | $37.76B | +7.41% |
Current Assets | $18.02B | $18.66B | -3.42% |
Total Liabilities | $9.3B | $8.41B | +10.66% |
Current Liabilities | $4.37B | $3.94B | +10.75% |
Stockholders' Equity | $31.26B | $29.35B | +6.48% |
Cash & Equivalents | $3.12B | $2.49B | +25.32% |
Long-Term Debt | $1.99B | $1.98B | +0.08% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $4.98B | $4.42B | +12.63% |
Investing Cash Flow | $-629.1M | $-2.47B | +74.51% |
Financing Cash Flow | $-3.72B | $-2.2B | -68.84% |
Dividends Paid | $370.3M | $0 | — |
Share Buybacks | $3.44B | $2.6B | +32.09% |
D&A | $543.7M | $482.9M | +12.59% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Margin | 24.9% | 28.1% | -3.15% |
Net Margin | 31.4% | — | — |
ROE | 14.4% | — | — |
ROA | 11.1% | — | — |
Current Ratio | $4.126 | — | — |
Debt to Equity | $0.298 | — | — |
Other companies in Biotechnology
Regeneron's FY2025 results showed modest revenue growth of 1.0% to $14.34B, but operating income fell 10.3% to $3.58B as R&D spending surged 14.0% to $5.85B. On the positive side, net income rose 2.1% to $4.50B, diluted EPS grew 8.2% to $41.48, and operating cash flow hit a record $4.98B, supporting $3.44B in buybacks and the company's first-ever dividend of $370.3M.
Regeneron's operating income declined 10.3% to $3.58B in FY2025 because R&D expenses grew 14.0% to $5.85B — far outpacing revenue growth of just 1.0% — compressing the operating margin from 28.1% to 24.9%. This reflects a deliberate strategic choice to invest heavily in the drug pipeline, accepting near-term margin pressure in pursuit of future growth.
In FY2025, Regeneron returned approximately $3.81B to shareholders, including $3.44B in share repurchases (up 32.1% from $2.60B in FY2024) and $370.3M in dividends, which appears to be the company's first dividend payment based on the prior-year comparison showing $0. This represented about 76.5% of the company's $4.98B in operating cash flow.
Yes, Regeneron's balance sheet and liquidity position remain very strong: the company holds $3.12B in cash, has a current ratio of 4.13x, and carries only $1.99B in long-term debt against $31.26B in stockholders' equity (debt-to-equity of just 0.30x). Operating cash flow of $4.98B grew 12.6% YoY, providing ample coverage for both its investment needs and shareholder returns.
Regeneron spent $5.85B on R&D in FY2025, equal to roughly 40.8% of total revenue — an exceptionally high ratio that signals aggressive pipeline investment but also significant execution risk. If key pipeline candidates fail in clinical trials, the company faces large sunk costs with limited near-term revenue to offset them, which could materially impact future earnings and margins.